About: Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients: Results from a real-life patient cohort

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients: Results from a real-life patient cohort Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients: Results from a real-life patient cohort
Creator	Laferl, Hermann Baumgartner, Sebastian Ely, Sarah Jilma, Bernd Karolyi, Mario Kelani, Hasan Mader, Theresa Omid, Sara Ott, Clemens Pawelka, Erich Seitz, Tamara Traugott, Marianna Turner, Michael Wenisch, Christoph Wochenschr, Wien Zoufaly, Alexander Baumgartner, · Ely, S Jilma, · Karolyi, M Kelani, · Laferl, · Mader, · Omid, · Ott, · Pawelka, E Seitz, · Traugott, · Turner, · Wenisch, · Zoufaly, ·
Source	Medline; PMC
abstract	BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with a high mortality. To date no trial comparing hydroxychloroquine (HCQ) and lopinavir/ritonavir (LPV/RTV) has been performed. METHODS: Hospitalized patients ≥18 years old with severe coronavirus disease 2019 (COVID-19) were treated with either HCQ or LPV/RTV if they had either respiratory insufficiency (SpO(2) ≤ 93% on room air or the need for oxygen insufflation) or bilateral consolidations on chest X‑ray and at least 2 comorbidities associated with poor COVID-19 prognosis. Outcomes investigated included in-hospital mortality, intensive care unit (ICU) admission, length of stay, PCR (polymerase chain reaction) negativity and side effects of treatment. RESULTS: Of 156 patients (41% female) with a median age of 72 years (IQR 55.25–81) admitted to our department, 67 patients fulfilled the inclusion criteria (20 received HCQ, 47 LPV/RTV). Groups were comparable regarding most baseline characteristics. Median time from symptom onset to treatment initiation was 8 days and was similar between the groups (p = 0.727). There was no significant difference (HCQ vs. LPV/RTV) in hospital mortality (15% vs. 8.5%, p = 0.418), ICU admission rate (20% vs. 12.8%, p = 0.470) and length of stay (9 days vs. 11 days, p = 0.340). A PCR negativity from nasopharyngeal swabs was observed in approximately two thirds of patients in both groups. Side effects led to treatment discontinuation in 15% of patients in the LPV/RTV group. CONCLUSION: No statistically significant differences were observed in outcome parameters in patients treated with HCQ or LPV/RTV but patients in the LPV/RTV group showed a numerically lower hospital mortality rate. Additionally, in comparison to other studies we demonstrated a lower mortality in patients treated with LPV/RTV despite having similar patient groups, perhaps due to early initiation of treatment.
has issue date	2020-08-10(xsd:dateTime)
bibo:doi	10.1007/s00508-020-01720-y
bibo:pmid	32776298
has license	no-cc
sha1sum (hex)	5ab33b078ab9769e60d29433cdefcc96d7b13879
schema:url	https://doi.org/10.1007/s00508-020-01720-y
resource representing a document's title	Hydroxychloroquine versus lopinavir/ritonavir in severe COVID-19 patients: Results from a real-life patient cohort
has PubMed Central identifier	PMC7416584
has PubMed identifier	32776298
schema:publication	Wien Klin Wochenschr
resource representing a document's body	covid:5ab33b078ab9769e60d29433cdefcc96d7b13879#body_text
is schema:about of	named entity 'admission' named entity 'Groups' named entity 'manuscript' named entity 'patients' named entity 'The' named entity 'chain reaction' named entity 'ICU' named entity 'SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2' named entity 'ADMISSION' named entity 'ICU' named entity 'INTENSIVE CARE UNIT' named entity 'PARAMETERS' named entity 'SIDE EFFECTS' named entity 'FEMALE' named entity 'HOSPITALIZED PATIENTS' covid:arg/5ab33b078ab9769e60d29433cdefcc96d7b13879 named entity 'patients' named entity 'PCR' named entity 'inclusion' named entity 'patients' named entity 'mortality rate' named entity 'negativity' named entity 'symptom' named entity 'groups' named entity 'observed' named entity 'comparing' named entity 'patients' named entity 'side effects' named entity 'groups' named entity 'comparable' named entity 'infection' named entity 'HCQ' named entity 'symptom' named entity 'coronavirus disease 2019' named entity 'HCQ' named entity 'HCQ' named entity 'PCR' named entity 'COVID' named entity 'ICU' named entity 'significant difference' named entity 'PCR' named entity 'Severe acute respiratory syndrome coronavirus 2' named entity 'HCQ' named entity 'polymerase chain reaction' named entity 'chest X-ray' named entity 'COVID-19' named entity 'Hydroxychloroquine' named entity 'lopinavir/ritonavir' named entity 'QTc' named entity 'off-label' named entity 'hospital laboratory'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software